ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
51 announcements with these filters
Sun Pharmaceutical has received shareholder approval to reclassify specific persons from the 'Promoter Group' to the 'Public' category, in compliance with SEBI Listing Regulations.
Sun Pharma reports Q1FY27 data showing diversified revenue of Rs 582 Bn for FY26. Key strategy remains scaling Innovative Medicines (22% of sales) and maintaining India market leadership (8.5% share).
Sun Pharma's subsidiaries signed a settlement agreement resolving antitrust litigation in the U.S. for a confidential amount, without any admission of wrongdoing.
Sun Pharma incorporates a new treasury subsidiary in GIFT City, Gandhinagar. Initial equity subscription is approximately ₹9.50 Crore for group treasury operations.
Sun Pharma has been assigned international issuer credit ratings of Baa1 by Moody’s and BBB+ by S&P. These investment-grade ratings reflect the company's strong financial profile.
Sun Pharma attended a White House signing ceremony, committing to Most Favored Nation pricing for U.S. Medicaid programs and future innovative medicine launches.
Sun Pharma seeks shareholder approval via postal ballot to reclassify three members of the 'Promoter Group' to the 'Public' category, effective upon requisite approval.
Sun Pharma announced a favorable court ruling in the US Lipitor antitrust litigation, which brings the long-standing matter substantially to a close.
Sun Pharmaceutical Industries Ltd received no-objection letters from the NSE and BSE to reclassify certain members from the promoter group to the public category.
Sun Pharma reported Q1FY27 revenue growth of 10.1% YoY to INR 151,836 million with an EBITDA margin of 28.9%. Growth was driven by Global Innovative Medicines and India formulations.
CRISIL reaffirmed Sun Pharmaceutical Industries' long-term bank facilities rating at 'CRISIL AAA/Stable'. The 'Rating Watch with Developing Implications' status has been officially removed.
Sun Pharma delivered strong double-digit growth led by India and global specialty medicines, though US generics face erosion and increased competition.
Sun Pharmaceutical Industries held its 34th Annual General Meeting, approving financial statements, director appointments, and a final dividend of Rs. 5 per share.
Sun Pharmaceutical informed the exchanges that its board meeting concluded on July 31, 2026, after adjourning for a break during the session.
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹15,300 Cr (+10.5% YoY) and net profit of ₹2,895 Cr (+27.0% YoY) for Q1 FY27.
Sun Pharma's partner, Philogen, has resubmitted the Marketing Authorization Application for Nidlegy to the European Medicines Agency for the treatment of melanoma.
Sun Pharma announced that Organon stockholders approved the proposed merger, moving the acquisition forward. The deal remains subject to remaining customary closing conditions.
Sun Pharma received SAHPRA approval to market generic semaglutide in South Africa. This marks the company's second market approval for the diabetes treatment after India.
Sun Pharmaceutical Industries scheduled a board meeting on July 31, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Sun Pharma reported FY26 sales of Rs 582 Bn with a 30.3% EBITDA margin. Strategy focuses on expanding the Global Innovative Medicines portfolio and maintaining leadership in the Indian market.
SUN PHARMA announces its 34th AGM on 31 Jul 2026 to adopt financials and declare ₹5/share dividend. Director reappointments and remuneration revisions are also on the agenda.
Sun Pharma has filed its Annual Report 2025-26 and Notice of 34th AGM. The report highlights global innovation and market leadership across key pharmaceutical segments.
Sun Pharma's independent director Mr. Gautam Doshi has been arrested in an unrelated matter. The company sees no impact on its operations or board.
Sun Pharmaceutical Industries scheduled its 34th AGM for July 31, 2026. The company fixed July 7, 2026, as the record date for a ₹5 per share dividend.
Sun Pharma reports Q4FY26 revenue growth of 13.6% and FY26 sales of INR 582 billion. Strategy focuses on Global Innovative Medicines and integrating the Organon acquisition.
Sun Pharmaceutical applied for reclassifying certain 'Promoter Group' shareholders into the 'Public' category. The regulatory move follows earlier internal company board intimations from May 2026.
Sun Pharma will present long-term follow-up data for UNLOXCYT at the ASCO 2026 meeting. The study shows durable responses and a manageable safety profile for laCSCC patients.
Sun Pharma delivered strong FY26 growth led by specialty medicines and India market share gains, despite US generic competition and regulatory headwinds.
Sun Pharma's board recommended a 500% final dividend for FY 2025-26. This move signals strong cash flows and a commitment to rewarding shareholders.
Sun Pharmaceutical's board approved promoter group reclassifications and adopted a revised Fair Disclosure Code. These administrative updates streamline regulatory compliance and internal governance frameworks.